

05-29-01

A
BOXSEA

NON-PROVISIONAL
UTILITY PATENT APPLICATION
TRANSMITTAL - 37 CFR 1.53(b)

☐ Duplicate
(check, if applicable)

05/25/01
JC939 U.S. PTO

JC978 U.S. PTO
09/866283
05/25/01

Assistant Commissioner for Patents
BOX PATENT APPLICATION
Washington, DC 20231

Attorney Docket No. 53650-5001
First Named Inventor: Rundell et al.
Express Mail Label No. EL524680672US
Total Pages of Transmittal Form: 2

Transmitted herewith for filing is the non-provisional utility patent application entitled:

COMPOSITIONS AND METHODS RELATING TO NUCLEIC ACID
REFERENCE STANDARDS

which is:

an ☒ Original; or

a ☐ Continuation, ☐ Divisional, or ☐ Continuation-in-part (CIP)
of prior Application No. ____.

Anticipated Group/Art Unit: ____ or Class ___, Subclass ____.

☐ This non-provisional patent application is based on Provisional Patent Application
No. ___, filed ____.

Enclosed are:

- ☒ Specification (including Abstract) and claims: 89 pages.
- ☒ Newly unexecuted Declaration (original/copy).
- ☐ Copy of Declaration from prior application.
- ☐ Separate Power of Attorney (including 37 CFR 3.73(b) statement, if applicable).
- ☒ 11 sheets of drawings (formal) plus one copy.
- ☐ Microfiche computer program (Appendix).
- ☒ Nucleotide and/or Amino Acid Sequence Submission, including:
 - ☒ Computer readable copy
 - ☒ Paper Copy (2 pages)
 - ☒ Verified Statement.
- ☐ Under PTO-1595 cover sheet, an assignment of the invention.
- ☐ Certified copy(ies) of __ Application No(s). __ filed __ is/are filed:
 - ☐ herewith
 - or
 - ☐ in prior application ____.
- ☒ Applicants, by their undersigned attorney, claim Small Entity Status under 37
C.F.R. §1.27 as ☐ an Independent Inventor, or ☒ a Small Business Concern, or
☐ a Non-Profit Organization.
- ☐ Preliminary Amendment.
- ☐ Information Disclosure Statement, PTO-1449, and cited references.
- ☐ Other: ____.

The filing fee is calculated as follows:

			SMALL ENTITY			LARGE ENTITY	
CLAIMS	NO. FILED	NO. EXTRA	BASIC FEE:			BASIC FEE:	
			\$355			\$710	
Total	32-20 =	12	X9	\$108.00	OR	X18	\$
Independent	6- 3=	3	X40	\$120.00	OR	X80	\$
[] Multiple Dependent Claims Present			\$135	\$	OR	\$270	\$
			TOTAL	\$583.00	OR	TOTAL	\$

[] The Commissioner is not authorized to charge the filing fee at this time as we elect to defer payment of the entire filing fee until receipt of a Notice to File Missing Parts.

[X] A check in the amount of **\$583.00** to cover the filing fee is enclosed.

[X] The Commissioner is hereby authorized to charge and/or credit **Deposit Account No. 50-0310 (Billing No. 53650-5001)** as noted below. A duplicate copy of this sheet is enclosed.

[X] Any overpayments or deficiencies in the above-calculated fee.

[] Filing fee in the amount of \$_____ as calculated above.

[X] Any additional fees required under 37 C.F.R. § 1.16 and § 1.17.

[] In the event that a Petition for Extension of Time is required during the prosecution of this application, but not submitted, please charge any extension fee under 37 C.F.R. § 1.136(a) to our Deposit Account noted above.

CORRESPONDENCE ADDRESS:

May 25, 2001
(Date)

By: *Raquel M Alvarez*
RAQUEL M. ALVAREZ, PH.D., J.D.

Registration No. 45,807
MORGAN, LEWIS & BOCKIUS, L.L.P.
1701 Market Street
Philadelphia, PA 19103-2921
Telephone: 215-963-5000
Direct Dial: 215-963-5403
Facsimile: 215-963-5299
E-Mail: ralvarez@morganlewis.com

[X] Customer Number or Bar Code Label: **028977**

Enclosures

036523 05301
T0550" E829860

EXPRESS MAIL NO.: EL524680672US

**PATENT
BOX SEQUENCE**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re:	Patent Application of RUNDELL <i>et al.</i>	: Group Art Unit: Not Yet Assigned : :
Appln. No.:	Not Yet Assigned	: Examiner: Not Yet Assigned : :
Filed:	May 25, 2001	: : :
For:	COMPOSITIONS AND METHODS RELATED TO NUCLEIC ACID REFERENCE STANDARDS	: Attorney Docket : No. 053650-5001 :

**STATEMENT TO SUPPORT FILING AND SUBMISSION
IN ACCORDANCE WITH 37 CFR §§ 1.821 THROUGH 1.825**

- (X) I hereby state, in accordance with the requirements of 37 C.F.R. §1.821(f), that the contents of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 C.F.R. §1.821(c) and (e), respectively are the same.
- (X) I hereby state that the submission filed in accordance with 37 C.F.R. §1.821(g) does not include new matter.
- () I hereby state that the submission filed in accordance with 37 C.F.R. §1.821(h) does not include new matter or go beyond the disclosure in the international application as filed.
- () I hereby state that the amendments, made in accordance with 37 C.F.R. §1.825(a), included in the substitute sheets of the Sequence Listing are supported in the application, as filed. I hereby state that the substitute sheets(s) of the Sequence Listing does(do) not include new matter.
- () I hereby state that the initial copy of the computer readable form, submitted in accordance with 37 C.F.R. §1.825(b), is the same as the amended Sequence Listing.

09366283 052501
T052501 052501

() I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 C.F.R. §1.825(d), contains identical data to that originally filed.

Respectfully submitted,

CLARK RUNDELL *et al.*

May 25, 2001
(Date)

By: Raquel M. Alvarez
RAQUEL M. ALVAREZ, Ph.D, J.D.
Registration No. 45,807
MORGAN, LEWIS & BOCKIUS, LLP
1701 Market Street
Philadelphia, PA 19103-2921
Telephone: (215) 963-5000
Direct Dial: (215) 963-5403
Facsimile: (877) 432-9652
E-Mail: ralvarez@morganlewis.com
Attorney for Applicants

RMA/GHL

Enclosures: Sequence Listing in Paper and Computer Readable Format

0956283-052501
T052501 E8299860